Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cocaine

Associated Studies:

Division Study Number Title Investigator(s) Release Date
CTN NIDA-CTN-0134 Identifying Regional “Hotspots” and Potential Correlates of Precipitated Withdrawal During Buprenorphine Induction in Fentanyl Users Through Prescriber Survey Responses and Patient Urine Drug Test Results (Buprenorphine-Precipitated Withdrawal Hotspots and Correlates) LaTrice Montgomery, Ph.D., T. John Winhusen, Ph.D.
DTMC NIDA-CSP-1033 Phase 2, Multi-Center Trial of Lorcaserin in the Treatment of Cocaine Use Disorder Shwe Gyaw, M.D.
DTMC NIDA-CPU-0010 Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CTO-0012 Phase 2, Double-Blind, Placebo-Controlled Trial Of Tiagabine For The Treatment Of Cocaine Dependence Eugene Somoza, M.D.
DTMC NIDA-CSP-1021 Double-Blind, Placebo-Controlled Multi-Center Trial Of Baclofen For The Treatment Of Cocaine Dependence Liza Gorgon, M.A.
DTMC NIDA-CSP-1019 Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System For The Treatment Of Cocaine Dependence Ahmed Elkashef, M.D., Paul J. Fudala, Ph.D.
DTMC NIDA-MDS-0003 Phase I, Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Cocaine And Ethanol And Oral Disulfiram John D. Roache, Ph.D.
DTMC NIDA-CTO-0007 Phase 2, Double-Blind, Placebo-Controlled Trial Of Cabergoline For The Treatment Of Cocaine Dependence Steven Shoptaw, Ph.D., Thomas F. Newton, M.D.
DTMC NIDA-CPU-0005 Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CPU-0004 Study of Interactions Between GBR 12909 and Cocaine Kathryn Cunningham, Ph.D., John Grabowski, Ph.D.
DTMC NIDA-CPU-0003 Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681 Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CPU-0002 Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CTO-0006 Cocaine-Metyrapone Interaction Study Bonita Singal, M.D., T. John Winhusen, Ph.D.
DTMC NIDA-CTO-0005 Double-Blind, Placebo-Controlled Trial Of Ondansetron For The Treatment Of Cocaine Dependence John D. Roache, Ph.D.
DTMC NIDA-CTO-0003 Assessment Of Potential Interactions Between Intravenous Cocaine And Tolcapone Thomas F. Newton, M.D.
DTMC NIDA-CTO-0002 Safety Evaluation Of Cocaine Treatment Medication, Modafinil: Interactions With Intravenous Cocaine Robert J. Malcolm, M.D., C. Lindsay DeVane, Pharm.D.
DTMC NIDA-MDS-0004 Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For The Treatment Of Cocaine Dependence Domenic Ciraulo, M.D.
DTMC NIDA-CTO-0001 Phase 2, Double-Blind, Placebo-Controlled Trial Of Reserpine For The Treatment Of Cocaine Dependence Eugene Somoza, M.D.
CTN NIDA-CTN-0052 A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC) T. John Winhusen, Ph.D.
CTN NIDA-CTN-0048 Cocaine Use Reduction with Buprenorphine (CURB) Walter Ling, M.D.
Subscribe to cocaine